Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-1805 ELDERLY
2024-515946-17-00Phase 3Authorised
- Sponsor
- IFCT
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by IFCT. Primary endpoint: Overall survival. Planned start Dec 2024; status: authorised.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515946-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515946-17-00.